The immune system protects the body from harmful things such as a virus, germs, and diseases like cancer. It is a network of cells, molecules: and organs present throughout the body. The immune system attacks the foreign substance that is found in the body. The body identifies and destroys the abnormal cells including cancerous cells. The inherent self-defense system comprises cells, which help the body in the identification of foreign molecules. Different pathways regulate various immune cells for distinguishing body's healthy cells and disease-causing foreign agents such as a virus: parasite, bacteria, fungi, and cancerous cells. To maintain the body's defense against the continuously evolving organisms, which try to attack the body in numerous ways, continuous modification of all the components of the immune system is essential. Sometimes, the continuously modifying immune system reacts against the body's cells, considering them as foreign agents, which results in the destruction of healthy tissues and becomes the cause of autoimmune diseases and cancers. The inherent state of unresponsiveness may also be observed due to the weakened body defense owing to the genetic reasons that result in immunodeficiency disease.
Technavio’s analysts forecast the global immunology market to grow at a CAGR of 4.57% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global immunology market for 2018-2022. To calculate the market size, the report considers the revenue generated from the immunology.
The market is divided into the following segments based on geography:
Technavio's report, Global Immunology Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
F. Hoffmann-La Roche
Johnson & Johnson
Other prominent vendors
Growing cases of infectious diseases
For a full, detailed list, view our report
For a full, detailed list, view our report
Key questions answered in this report
What will the market size be in 2022 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
Technavio Announces the Publication of its Research Report – Global Immunology Market 2018-2022
Technavio recognizes the following companies as the key players in the global immunology market: AbbVie, Amgen, F. Hoffmann-La Roche, and Johnson & Johnson.
Other Prominent Vendors in the market are: Angimmune, Bionor Pharma, Boston Biomedical, Celgene, Cellectar Biosciences, eFFECTOR Therapeutics, Forty Seven, HANSOH, Immatics Biatechnologies, lmmunovaccine, Karyopharm Therapeutics, MabVax Therapeutics, MedImmune, MOLOGEN, Neon Therapeutics, NewLink Genetics, Novartis, ONCOQUEST, and Oncotherapeutics.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is significant pipeline. There are multiple promising immunological agents in the pipeline, which boost the market growth after their approval. The approval of new therapeutic agents broadens the options available for the treatment and thus leads to the increase in demand for the therapeutic regimen. There are approximately 51 molecules under different clinical trial stages globally. Out of them, 22 molecules are in Phase II, four molecules are in Phase III, 16 molecules are in Phase I, and remaining are in Phase I/Il clinical trials. One of the most promising molecules under development from AbbVie is risankizumab (ABBY-066). Boehringer Ingelheim and AbbVie are jointly working on the molecule to get approval for new indications such as psoriasis, psoriatic arthritis, and Crohn's disease. This combination is currently going through Phase III clinical trial for psoriasis and Phase II for psoriatic arthritis and Crohn's disease.”
According to the report, one of the major drivers for this market is growing cases of infectious diseases. Infectious diseases such as hepatitis and acquired immunodeficiency syndrome (AIDS) are rampant globally. When the body’s immune system is unable to resist the invading pathogens or microbes, it gives way to infections. Infectious diseases such as hepatitis and AIDS can be treated by immunomodulators. Agents that help in boosting the immunity of the human body help in resisting pathogens. According to the CDC, there are more than a million AIDS-affected people in the US. With the rising incidences of infectious diseases, the demand for immunology products will increase in the coming years.
AbbVie, Amgen, F. Hoffmann-La Roche, Johnson & Johnson, Angimmune, Bionor Pharma, Boston Biomedical, Celgene, Cellectar Biosciences, eFFECTOR Therapeutics, Forty Seven, HANSOH, Immatics Biatechnologies, lmmunovaccine, Karyopharm Therapeutics, MabVax Therapeutics, MedImmune, MOLOGEN, Neon Therapeutics, NewLink Genetics, Novartis, ONCOQUEST, and Oncotherapeutics.